Data mining and safety analysis of traditional immunosuppressive drugs: a pharmacovigilance investigation based on the FAERS database

References

• Ponticelli C, Glassock RJ. Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol. 2019 Dec;32(6):851–870. doi: 10.1007/s40620-019-00602-5
   PubMed Web of Science ®Google Scholar
• Franz L, Frosolini A, Parrino D, et al. Ototoxicity of immunosuppressant drugs: a systematic review. J Int Adv Otol. 2022 Mar;18(2):167–176.
   PubMed Web of Science ®Google Scholar
• Naccache JM, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Jan;10(1):26–34.
   PubMed Web of Science ®Google Scholar
• Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED. Bevacizumab and gastrointestinal perforations: a review from the FDA adverse event reporting system (FAERS) database. Aliment Pharmacol Ther. 2021 Nov;54(10):1290–1297. doi: 10.1111/apt.16601
   PubMed Web of Science ®Google Scholar
• Schaeffer C, Booton L, Halleck J, et al. Big data management in US hospitals: benefits and barriers. Health Care Manag (Frederick). 2017 Jan;36(1):87–95.
   PubMedGoogle Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022 Apr;21(4):563–572.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007 Nov 10;25(32):5121–7. doi: 10.1200/JCO.2007.12.4784
   PubMed Web of Science ®Google Scholar
• Kadoyama K, Sakaeda T, Tamon A, et al. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and drug administration adverse event reporting system. Biol Pharm Bull. 2012;35(6):967–70. doi: 10.1248/bpb.35.967
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Hu W, Chen L, Li H, et al. Eye disorders associated with newer antiepileptic drugs: a real-world disproportionality analysis of FDA adverse event reporting system. Seizure. 2022 Mar;96:66–73. doi: 10.1016/j.seizure.2022.01.011
   PubMed Web of Science ®Google Scholar
• Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol. 1990 Aug;1(2):162–79. doi: 10.1681/ASN.V12162
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009 Feb;4(2):481–508. doi: 10.2215/CJN.04800908
   PubMed Web of Science ®Google Scholar
• Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011 Oct 2;17(10):1304–9. doi: 10.1038/nm.2497
   PubMed Web of Science ®Google Scholar
• European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 multicentre liver study group. Lancet. 1994 Aug 13;344(8920):423–8. doi: 10.1016/S0140-6736(94)91766-3
   PubMed Web of Science ®Google Scholar
• Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494–500. doi: 10.1056/NEJM199602223340803
   PubMed Web of Science ®Google Scholar
• A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994 Oct 27;331(17):1110–5. doi: 10.1056/NEJM199410273311702
   PubMed Web of Science ®Google Scholar
• Mecadon K. Managing side effects of immunosuppressants. R I Med J. 2013 Feb 1;104(1):31–33.
   Google Scholar
• Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987 Dec;17(6):962–71.
   PubMed Web of Science ®Google Scholar
• Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol. 2003 Jul;30(7):1508–12.
   PubMed Web of Science ®Google Scholar
• Massari P, Duro-Garcia V, Girón F, et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc. 2005 Mar;37(2):916–9.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–62.
   PubMed Web of Science ®Google Scholar
• Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004 May;2(5):410–417.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Herfarth H, Katz J, et al. American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017 Sep;153(3):835–857.e6.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000 Jun;118(6):1025–30.
   PubMed Web of Science ®Google Scholar
• Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005 Oct 8;331(7520):810. doi: 10.1136/bmj.38569.471007.AE
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation. 2005 Jul 15;80(1):41–6. doi: 10.1097/01.TP.0000162980.68628.5A
   PubMed Web of Science ®Google Scholar
• Chambers DC, Yusen RD, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017 Oct;36(10):1047–1059.
   PubMed Web of Science ®Google Scholar
• McKee M, Segev D, Wise B, et al. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg. 1997 May;32(5):688–90.
   PubMed Web of Science ®Google Scholar
• Neu AM, Ho PL, Fine RN, et al. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant. 2003 Jun;7(3):217–22.
   PubMed Web of Science ®Google Scholar
• Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol. 2002 Mar;17(3):141–149.
   PubMed Web of Science ®Google Scholar
• Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant. 2005 Aug;9(4):498–503.
   PubMed Web of Science ®Google Scholar
• McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006 Jul;6(7):1578–85.
   PubMed Web of Science ®Google Scholar
• Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006 Oct 18;2006(4):Cd005161.
   PubMedGoogle Scholar
• Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant. 2016 Jan;16(Suppl 2):11–46.
   PubMedGoogle Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998 Oct 1;92(7):2303–14.
   PubMed Web of Science ®Google Scholar
• Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000 Sep 15;96(6):2062–8.
   PubMed Web of Science ®Google Scholar
• Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis. 2006 Jan;13(1):47–55. doi: 10.1053/j.ackd.2005.11.001
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562–75. doi: 10.1056/NEJMoa067411
   PubMed Web of Science ®Google Scholar
• Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF study. Transplantation. 2008 May 15;85(9):1261–9. doi: 10.1097/TP.0b013e31816b4388
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Pʼng CH, Oʼconnell PJ, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation. 2016 Aug;100(8):1723–1731.
   PubMed Web of Science ®Google Scholar
• Klintmalm G, Bohman SO, Sundelin B, et al. Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period. Lancet. 1984 Oct 27;2(8409):950–954. doi: 10.1016/S0140-6736(84)91166-8
   PubMed Web of Science ®Google Scholar
• Henny FC, Kleinbloesem CH, Moolenaar AJ, et al. Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. Transplantation. 1985 Sep;40(3):261–5.
   PubMed Web of Science ®Google Scholar
• Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States multicenter FK506 kidney transplant group. Transplantation. 1996 Oct 15;62(7):900–5. doi: 10.1097/00007890-199610150-00005
   PubMed Web of Science ®Google Scholar
• Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021 Jan;74(1):148–155.
   PubMed Web of Science ®Google Scholar
• Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020 Jul;72(1):287–304.
   PubMed Web of Science ®Google Scholar
• Yin S, Wang X, Song T. Tacrolimus Use and COVID-19 infection in patients after solid organ transplantation. Gastroenterology. 2021 Aug;161(2):728–730.e1. doi: 10.1053/j.gastro.2021.01.223
   PubMed Web of Science ®Google Scholar
• Belli LS, Fondevila C, Cortesi PA, et al. Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. Gastroenterology. 2021 Mar;160(4):1151–1163.e3. doi: 10.1053/j.gastro.2020.11.045
   PubMed Web of Science ®Google Scholar
• Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004 Feb;4(2):222–30. doi: 10.1046/j.1600-6143.2003.00325.x
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001 Apr 27;71(8):1065–8. doi: 10.1097/00007890-200104270-00010
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the north American pediatric renal transplant cooperative study. Pediatr Transplant. 2002 Oct;6(5):396–9.
   PubMed Web of Science ®Google Scholar
• Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004 Jan;4(1):87–93. d oi:
   PubMed Web of Science ®Google Scholar
• Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation. 2005 Nov 15;80(9):1174–1180. doi: 10.1097/01.tp.0000169035.10572.c6
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019;59(2):72–92. doi: 10.3960/jslrt.19007
   PubMed Web of Science ®Google Scholar
• Ross S, Rajwal SK, Sugarman I, et al. Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):229–231.
   PubMed Web of Science ®Google Scholar
• Hickey CL, Romee R, Nikiforow S, et al. A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide. Haematologica. 2020 Jul;105(7):e379–e381.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004 Jun;50(6):1740–1751. doi: 10.1002/art.20311
   PubMed Web of Science ®Google Scholar
• Menke DM, Griesser H, Moder KG, et al. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 2000 Feb;113(2):212–8.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008 Feb 25;168(4):378–381. doi: 10.1001/archinternmed.2007.107
   PubMedGoogle Scholar
• Váróczy L, Gergely L, Zeher M, et al. Malignant lymphoma-associated autoimmune diseases–a descriptive epidemiological study. Rheumatol Int. 2002 Nov;22(6):233–237.
   PubMed Web of Science ®Google Scholar
• Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene. 2004 Aug 23;23(38):6524–34.
   PubMed Web of Science ®Google Scholar
• Subramaniam K, Yeung D, Grimpen F, et al. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014 Mar;44(3):287–290.
   PubMed Web of Science ®Google Scholar
• Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan;108(1):99–105.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009 Nov 7;374(9701):1617–25. doi: 10.1016/S0140-6736(09)61302-7
   PubMed Web of Science ®Google Scholar
• Bašić Kinda S, Duraković N, Dotlić S, et al. Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant. Leuk Lymphoma. 2013 Jun;54(6):1334–5.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol. 2012 Aug;83(2):283–292. doi: 10.1016/j.critrevonc.2011.10.001
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020 Dec;45(6):1434–1441.
   PubMed Web of Science ®Google Scholar
• Kumar R, Vidaurre J, Gedela S. Valproic acid-induced coagulopathy. Pediatr Neurol. 2019 Sep;98:25–30. doi: 10.1016/j.pediatrneurol.2019.04.019
   PubMed Web of Science ®Google Scholar
• Kubota T, Okamura T, Hayashi S, et al. Transient dysfibrinogenemia and cerebral thrombosis following remission induction therapy for acute lymphoblastic leukemia. Rinsho Ketsueki. 1990 Sep;31(9):1517–1522.
   PubMedGoogle Scholar
• Fujieda H, Hojo H, Ohyashiki JH, et al. Transient hypofibrinogenemia induced by prednisolone in a case of acute lymphoblastic leukemia. Rinsho Ketsueki. 1989 Jul;30(7):1037–1041.
   PubMedGoogle Scholar
• He T, Ling J, Yang J. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis. Sci Rep. 2023 Jun 3;13(1):9050.
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Majima T, Onodera T, et al. Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis. Int J Hematol. 2012 Dec;96(6):781–5.
   PubMed Web of Science ®Google Scholar
• Martis N, Chirio D, Queyrel-Moranne V, et al. Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Joint Bone Spine. 2017 May;84(3):369–370.
   PubMed Web of Science ®Google Scholar
• Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009 Apr;145(1):24–33.
   PubMed Web of Science ®Google Scholar
• Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993 Aug;34(8):1081–5.
   PubMed Web of Science ®Google Scholar
• Moreso F, Serón D, Morales JM, et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant. 1998 Jun;12(3):198–205.
   PubMed Web of Science ®Google Scholar
• Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001 Mar;16(3):271–282. doi: 10.1007/s004670000523
   PubMed Web of Science ®Google Scholar
• Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-Associated vasculitis: a meta-analysis of observational studies. PloS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int. 2004 Nov;17(10):609–16.
   PubMed Web of Science ®Google Scholar
• Subedi S, Gong Y, Chen Y, et al. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019;13:2491–2502. doi: 10.2147/DDDT.S200147
   PubMed Web of Science ®Google Scholar
• Jering KS, McGrath MM, Mc Causland FR, et al. Excess mortality in solid organ transplant recipients hospitalized with COVID-19: a large-scale comparison of SOT recipients hospitalized with or without COVID-19. Clin Transplant. 2022 Jan;36(1):e14492.
   PubMed Web of Science ®Google Scholar